Visão geral da empresa
Entrada Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing a novel class of medicines designed to engage intracellular targets that were historically considered inaccessible to therapeutic intervention. By utilizing its proprietary Endosomal Escape Vehicle technology, the firm aims to transform patient outcomes within the highly specialized biotechnology sector of the healthcare industry. The company currently maintains a market capitalization of $548.23M and employs approximately 152 individuals to execute its research and development pipeline. With reported annual revenue of $25.42M, these financial figures indicate that the company functions as a capital-intensive entity in the early-to-mid stages of commercialization, where revenue generation is secondary to advancing clinical candidates, resulting in a valuation that is not strictly tied to current sales but rather to potential future milestones.
Saúde financeira
The company reported a revenue of $25.42M over the trailing twelve months, while posting a net income of -$143,750,000 and an EBITDA of -$151,902,000, highlighting a significant disparity between top-line performance and bottom-line profitability due to substantial operating expenses inherent in clinical-stage development. The free cash flow stood at -$76,957,752, which reflects a burn rate that limits immediate financial flexibility and necessitates continuous access to external capital markets to fund ongoing operations and research initiatives. Margin analysis reveals a gross margin of 0.0%, an operating margin of -3103.0%, and a profit margin of 0.0%, indicating that current revenue levels are insufficient to cover the high fixed costs associated with clinical trials and manufacturing scale-up, resulting in negative returns on every dollar of sales. In terms of solvency, the company holds $295.70M in cash against $50.93M in debt, supported by a debt-to-equity ratio of 16.64, suggesting a balance sheet that is leveraged yet possesses a significant cash buffer relative to its short-term obligations. Liquidity is robust as evidenced by a current ratio of 12.53, which implies that the company possesses more than twelve times the cash and equivalents needed to cover its short-term liabilities without immediate distress. Finally, the return on equity is -39.1% and the return on assets is -21.6%, metrics that reveal that management is currently deploying capital into high-risk, high-potential projects that have not yet generated positive shareholder returns or asset appreciation.
Avaliação de valorização
Valuation metrics for Entrada Therapeutics present a complex picture due to the lack of traditional profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -4.16, implying that the market is pricing the stock based on expected future earnings recovery rather than current performance history. The price-to-book ratio stands at 1.68, indicating that the market values the company at a premium of 68% over its net asset book value, which often reflects the intrinsic value of the intellectual property and the potential of the clinical pipeline rather than tangible assets alone. Alternative valuation multiples provide further context, with a price-to-sales ratio of 21.57 and an EV/EBITDA of -1.78, suggesting that investors are willing to pay a high multiple for each dollar of revenue in anticipation of a successful transition from clinical trials to commercial launch. The stock's trading range over the past year has been bounded by a 52-week high of $14.36 and a 52-week low of $4.93, placing the current valuation within a wide band of volatility typical for biotech firms awaiting regulatory approval or pivotal data readouts. The beta coefficient of -0.15 is a unique statistic for this sector, suggesting that the stock's price movements have historically moved inversely or with very low correlation to the broader market index, offering a distinct risk profile compared to large-cap equities.
Growth & Income
Growth dynamics are characterized by a year-over-year revenue decline of -96.5% and earnings growth listed as N/A, illustrating a typical contraction in sales for a company where revenue recognition is sporadic and dependent on specific commercialization milestones rather than consistent quarterly growth. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is clear that Entrada Therapeutics reinvests all available financial resources back into its R&D efforts and clinical programs rather than distributing income to shareholders. The absence of a payout ratio means that the company retains all earnings, albeit negative ones, to extend its cash runway and advance its therapeutic candidates through the rigorous clinical trial process required for FDA approval. Overall, the growth and income profile is defined by a strategic focus on long-term value creation through clinical advancement rather than short-term income generation or dividend yields, leaving investors exposed to the binary risk of the company's product pipeline success without the cushion of regular income distributions.